Scholarlink

Introduction <p>Pancreatic cancer has a poor prognosis. The present systematic review and meta-analysis evaluated progression free survival (PFS) and overall survival (OS) after gemcitabine-based therapy nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil for metastatic pancreatic ductal adenocarcinoma (PDAC) patients.</p> Methods <p>The present systematic review and meta-analysis was registered in PROSPERO with id no. CRD42024608206. A systematic literature review was performed according to the PRISMA checklist, consulting Embase, PubMed, Scopus, and Web of Science databases.</p> Results <p>Screened studies considered median values for PFS and Hazard Ratio for OS. Heterogeneity among the selected studies was statistically significant both for PFS (<i>P</i> &lt; 0.001; tau<sup>2</sup> = 0.72; I<sup>2</sup> = 98.67%) and OS (<i>P</i> = 0.010; tau<sup>2</sup> = 0.24; I<sup>2</sup> = 87.76%). Data indicated that PFS median values were longer in the experimental group than in the control one (Z = 4.46; <i>P</i> &lt; 0.001). The results for OS showing no statistically significant difference between groups (HR = 0.79; <i>P</i> = 0.45).</p> Conclusion <p>The present findings confirmed the outcomes improvements provided by nal-IRI for PDAC patients; however, our results should be interpreted cautiously. More data regarding the role of performance status, patient population, the line of treatment, and the role of eventual sequencing various regimens are awaited.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil for metastatic pancreatic ductal adenocarcinoma following gemcitabine-based therapy. A systematic review and meta-analysis of randomized controlled trials

  • 期刊论文

  • 发表日期：

    2026年3月31日

查看全文
  • Elsa Vitale,
  • Alessandro Rizzo,
  • Lorenza Maistrello,
  • Angela Monica Sciacovelli,
  • Raffaele De Luca,
  • Anna Albano,
  • Annarita Fanizzi,
  • Raffaella Massafra,
  • Claudio Lotesoriere,
  • Gennaro Gadaleta-Caldarola,
  • Salvatore Pisconti,
  • Oronzo Brunetti

摘要

Introduction

Pancreatic cancer has a poor prognosis. The present systematic review and meta-analysis evaluated progression free survival (PFS) and overall survival (OS) after gemcitabine-based therapy nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil for metastatic pancreatic ductal adenocarcinoma (PDAC) patients.

Methods

The present systematic review and meta-analysis was registered in PROSPERO with id no. CRD42024608206. A systematic literature review was performed according to the PRISMA checklist, consulting Embase, PubMed, Scopus, and Web of Science databases.

Results

Screened studies considered median values for PFS and Hazard Ratio for OS. Heterogeneity among the selected studies was statistically significant both for PFS (P < 0.001; tau2 = 0.72; I2 = 98.67%) and OS (P = 0.010; tau2 = 0.24; I2 = 87.76%). Data indicated that PFS median values were longer in the experimental group than in the control one (Z = 4.46; P < 0.001). The results for OS showing no statistically significant difference between groups (HR = 0.79; P = 0.45).

Conclusion

The present findings confirmed the outcomes improvements provided by nal-IRI for PDAC patients; however, our results should be interpreted cautiously. More data regarding the role of performance status, patient population, the line of treatment, and the role of eventual sequencing various regimens are awaited.